Pfizer To Buy Trillium For $2.26bn In A Hematology Pipeline Play
Pfizer will gain two clinical-stage immuno-oncology assets targeting the SRRPα-CD47 axis that it hopes could reach the market in the 2025-2030 timeframe.
You may also be interested in...
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
The deal is a nod for Arena's turnaround strategy and could be the start of an active deal-making period for Pfizer, flush with cash.
Merck said it is giving the FTC more time to review the acquisition, but the shift also gives the company leeway to convince any reluctant Acceleron shareholders to trade their shares for cash.